As a core domain of precision medicine, cell therapy requires an exceptionally stringent environment for its manufacturing process—demanding strict sterility, contamination control, and the preservation of cell viability. Cell therapy isolators, serving as critical equipment, directly determine the safety, efficacy, and regulatory compliance of the final cell-based products.
This guide—informed by the industry standard "Aseptic processing of health care products—Part 6: Isolator systems" (YY/T 0567.6—2022 / ISO 13408-6:2021), which outlines essential requirements for the specification, selection, and qualification of isolator systems—addresses the practical needs of clinical, research, and manufacturing environments. It provides a systematic overview of the core prerequisites, key performance indicators, selection processes, and important considerations for choosing an isolator. The goal is to assist relevant organizations—such as hospitals, research institutes, and biopharmaceutical companies—in making informed selection decisions, mitigating procurement risks, ensuring a precise match between equipment and application scenarios, and balancing cost control with long-term operational convenience.
I. Core Prerequisites for Selection
Defining Application Scenarios and Regulatory Compliance Baselines
Before beginning the selection process, it is essential to clearly define the core application scenarios and the minimum regulatory compliance requirements. This serves as the foundation for all subsequent selection efforts, helping to prevent equipment underutilization or compliance risks resulting from a mismatch between the equipment and its intended use, while also establishing the scope for evaluating specific performance indicators.
Defining Application Scenarios
Cell Therapy Isolators
01: Clinical-Grade Applications
Designed for use in hospital-based cell therapy centers, these isolators are intended for the preparation of cell products—such as CAR-T cells, stem cells, and other immune cells—for clinical infusion. The primary requirements include ensuring aseptic processing, preventing cross-contamination, and maintaining full traceability. The equipment must be capable of handling clinical-scale batch production and supporting the entire workflow, including cell isolation, cultivation, washing, and cryopreservation. In certain clinical settings, the isolator may also need to support automated pneumatic docking with incubators—requiring a docking time of ≤1 minute, with no need for re-sterilization of the docking interface. Furthermore, the system should incorporate dual-control mechanisms (mechanical and software-based scanning) to ensure operational safety. Additionally, the isolator must be compatible with laminar flow fan filter units (FFU) and integrated heating systems to ensure precise temperature uniformity and effective dehumidification during pre-processing.
02: Research-Grade Applications
Designed for research institutes and university laboratories, these systems are used for fundamental research and process optimization in cell therapy. They require a high degree of operational flexibility and parameter adjustability, accommodating small-batch processing of diverse cell types. While full clinical regulatory compliance is not required, the accuracy and reproducibility of experimental results must be guaranteed. In research settings, the emphasis is placed on equipment innovation and precision, allowing for parameter adjustments tailored to various experimental protocols and supporting exploratory research across a wide range of cell types.
03: Large-Scale Production Applications
Intended for biopharmaceutical companies, these systems are used for the large-scale manufacturing of cell therapy products. Key requirements include high stability, a high level of automation, and scalability. The equipment must be compatible with continuous production workflows, meet full-process GMP (Good Manufacturing Practice) compliance, and support the processing of large volumes of cells across multiple batches. Current large-scale production trends favor intelligent systems—integrating fully enclosed isolators, six-axis robots, and AI-based visual recognition—to enable entirely hands-free cell preparation. Such systems can process up to 10 billion cells per batch, delivering 8–10 times the capacity of manual operations while significantly reducing cell mortality and mutation rates.
Cell therapy isolators are classified as medical devices; therefore, their selection must strictly adhere to relevant industry standards and regulatory requirements. Key compliance points include:
Compliance with the YY/T 0567.6—2022 / ISO 13408-6:2021 standard, which outlines requirements for the specification, selection, qualification, bio-decontamination, validation, operation, and control of isolator systems, ensuring they meet the demands of aseptic processing. Furthermore, the equipment and its functional components must be certified under the ISO 9001 quality management system, with relevant documentation provided as evidence. While this standard does not apply to Restricted Access Barrier Systems (RABS) or isolators used for sterility testing—though some of its principles may be referenced—it also does not cover specific requirements for biosafety containment. Equipment must support data traceability, including the recording of operational parameters, environmental conditions, and biological decontamination processes. This ensures compliance with GMP requirements for production process traceability, facilitating future audits and regulatory inspections. For large-scale production equipment, intelligent sample management and traceability are also essential, enabling rapid and precise retrieval of sample information—even in cryogenic environments.
Pressure control requirements should be defined based on the risk level of the cell type being processed. For routine aseptic cell preparation, positive-pressure isolators are preferred to prevent the ingress of external contaminants. When handling highly active, infectious, or otherwise hazardous cells, negative-pressure isolators must be used to protect operators and the surrounding environment; indeed, some clinical programs explicitly mandate the use of negative-pressure control systems for cell isolators.
II. Key Selection Criteria
Focusing on Critical Performance Indicators
The core performance of a cell therapy isolator directly determines the quality of cell preparation and operational safety. Selection should prioritize the following six dimensions—weighted according to specific application scenarios—while also considering equipment stability and ease of operation and maintenance.
(i) Aseptic Environment and Contamination Control
Sterility is a fundamental requirement in cell therapy. Through physical barriers and pneumatic protection, an isolator must isolate the critical processing zone from the external environment and operators, thereby minimizing the risk of contamination. This is the primary consideration during the selection process and a central focus of GMP audits conducted by regulatory authorities.
Q: Cleanliness Class
A: Equipment intended for clinical or production use must meet GMP Grade A (Class 100) cleanliness standards. For research-grade equipment, GMP Grade B (Class 1000) or higher may be selected based on specific requirements. Air supplies must be filtered through High-Efficiency Particulate Air (HEPA) filters—or filters of an even higher grade—to ensure that the air entering the isolator is free from particulate matter and microbial contamination. Filters must be replaceable and subject to periodic testing. Furthermore, maintenance of the fan unit and replacement of filters should be convenient; preference should be given to equipment that allows for maintenance and filter replacement from the front of the isolator.
Q: Biological Decontamination System
A: An automated biological decontamination system is required, with a preference for Vaporized Hydrogen Peroxide (VHP). VHP is the current industry standard due to its thorough decontamination efficacy, lack of residue, and absence of damage to cells. The decontamination process must be programmable—allowing for the configuration of parameters such as concentration, duration, and temperature—and must record decontamination data to ensure the process is both traceable and reproducible. Furthermore, the system must be compatible with the materials used for the interior surfaces of the isolator (e.g., stainless steel, polymers) to ensure that the decontaminant does not cause corrosion or damage, which could compromise seals and lead to contamination risks.
Q: Containment and Leak Control
A: The equipment must feature robust containment, verified through leak testing to ensure no leakage occurs, thereby preventing the ingress of external contaminants or the compromise of the internal sterile environment. The leak rate must comply with industry standards. During operation, the pressure differential must be monitored in real time; if the pressure falls outside the established range, an alarm must be triggered to alert operators to take corrective action. For isolators installed through a wall, the interface must be sealed using specialized flanges, silicone gaskets, and fire-rated sealant to ensure a gap-free fit. All power and data cables must be routed through airtight feedthrough boxes; direct drilling of holes is strictly prohibited.
Q: Cross-Contamination Prevention
A: When processing multiple batches or various types of cells, the system must incorporate independent operating chambers or structures that allow for rapid cleaning to prevent cross-contamination between batches. The transfer of materials into and out of the unit must be conducted via dedicated transfer systems (such as transfer chambers or rapid transfer ports), maintaining a sterile environment throughout the process. All materials and components entering the isolator must either be pre-sterilized or undergo biological decontamination at the transfer port. Additionally, the room housing the isolator should be a dedicated, independent functional space, with a background cleanliness level of at least Grade D (ISO 8). Material flow paths should follow a "unidirectional flow" principle with "no-contact handovers" to minimize pressure fluctuations and the risk of contamination.
(II) Operational Flexibility and Adaptability
The operational flexibility of an isolator directly impacts work efficiency. It must be integrated with the cell preparation workflow to ensure the equipment can accommodate various operational requirements. At the same time, it should prioritize ease of use for operators, thereby minimizing both the risk of contamination—often introduced by human intervention—and potential losses in efficiency.
Flexibility and Adaptability
Isolators for Cell Therapy
01: Chamber Dimensions and Layout
The dimensions of the chamber should be selected based on the volume of cells processed in a single batch. For instance, some clinical-grade projects may require an isolator with external dimensions of at least 3500 mm (length) × 900 mm (width) × 2670 mm (height) and internal dimensions of at least 2500 mm (length) × 600 mm (width) × 930 mm (height) to accommodate large-volume processing. Clinical-grade equipment must be compatible with the placement and handling of standard items such as cell culture flasks, centrifuge tubes, and bioreactors, while production-grade equipment must support the transfer and manipulation of large-volume containers (e.g., culture bags). The internal layout should be well-planned, providing sufficient workspace to prevent operational interference. Additionally, the isolator should be elevated 10–15 cm from the floor to facilitate cleaning and the inspection of utility lines, while preventing the accumulation of water or debris.
02: Design of Operational Interfaces
The unit should be equipped with an adequate number of glove ports (4–6 are recommended). The gloves themselves must be made of materials resistant to tearing, puncture, and biological decontamination agents. Their design should offer sufficient flexibility to allow operators to perform precise tasks—such as cell isolation, inoculation, and media exchange—with accuracy. Replaceable glove systems can be incorporated to simplify routine maintenance; it is recommended that gloves be replaced every 3–6 months to prevent degradation or rupture. Depending on the specific application, additional access ports or observation windows may be included. Observation windows must maintain high clarity for real-time monitoring of internal processes and must be capable of withstanding exposure to biological decontamination agents, cleaning agents, and disinfectants.
03: Material Transfer System
The transfer method must be selected based on the specific application scenario. Closed isolators require dedicated transfer chambers; these maintain a sterile environment via a solid physical barrier during operation, allowing only designated batches of materials to pass through. Open isolators may be equipped with features such as "mouse-hole" (small-aperture) ports or depyrogenation channels to facilitate continuous material transfer, while relying on unidirectional airflow or positive-pressure protection to preserve the integrity of the isolated environment. Transfer systems must be appropriately sized for the materials, designed for ease of operation, and capable of effectively maintaining the internal sterile environment to minimize the risk of contamination.
04: System Compatibility
The system must support the processing of various cell types (e.g., stem cells, immune cells, adherent cells, and suspension cells). Clinical-grade and production-grade equipment should be compatible with the full range of instruments used in cell preparation—such as centrifuges, incubators, and pipetting devices—enabling seamless integration and reducing the need for manual intervention. Research-grade equipment should offer flexible parameter adjustment to accommodate diverse experimental protocols. Furthermore, equipment intended for large-scale production must incorporate a closed-circuit tubing system; the materials used for this tubing must undergo biocompatibility verification and demonstrate high pressure resistance and sealing integrity.
(III) Cell Viability Protection
The efficacy of cell therapy products is contingent upon cell viability. Consequently, an isolator must possess robust environmental control capabilities to prevent any decline in cell viability caused by environmental fluctuations during the preparation process—a key feature that distinguishes these systems from standard sterile isolators.
✅ Temperature and Humidity Control: The internal temperature must be stably maintained at 37°C ± 0.5°C (to suit human cell culture requirements), with relative humidity controlled between 45% and 65%. Temperature uniformity must meet industry standards to prevent localized temperature variations that could lead to inconsistent cell viability. Systems may be equipped with integrated heaters to enhance the efficiency of pre-processing dehumidification and improve temperature control precision, catering to the specific culture requirements of different cell types. Some advanced, intelligent systems can even utilize AI algorithms to automatically adjust temperature and humidity parameters.
✅ Gas Environment Control: The system must support precise regulation of CO₂ concentration (typically 5% ± 0.1%). For certain cell types—such as stem cells—it must also accommodate a hypoxic environment (O₂ concentration of 2%–5%). Gas regulation requires rapid response and minimal concentration fluctuations to ensure a stable metabolic environment for the cells. Gas supply lines must be sterilized to prevent contamination and equipped with gas filtration units that undergo regular replacement and maintenance.
✅ Prevention of Cell Damage: Airflow within the processing chamber must be smooth and free of turbulence to prevent mechanical stress or damage to the cells. The design of glove ports and transfer hatches must minimize mechanical friction and pressure fluctuations during operation, thereby reducing the risk of cell rupture. Any biological decontamination agents used must leave no residue, as residual chemicals could inhibit cell viability; a VHP (vaporized hydrogen peroxide) decontamination method—which is non-damaging to cells—is preferred.
(IV) Level of Automation and Intelligence
The level of automation and intelligence directly influences the efficiency, consistency, and reproducibility of cell preparation. It reduces human error and lowers the physical workload for operators. This is particularly critical for large-scale production and high-frequency clinical applications, representing the current development trend for isolators used in cell therapy.
Q: Automated Operational Functions
A: For clinical- or production-grade equipment, priority should be given to systems capable of automated cell separation, inoculation, media exchange, and washing. Such systems enable fully autonomous, hands-free processing, minimizing the risk of contamination associated with human intervention. They support preset protocols and batch processing to meet the demands of multi-batch cell production; some systems can even operate unattended 24 hours a day, significantly enhancing preparation efficiency.
Q: Intelligent Monitoring and Early Warning
A: Systems should be equipped with high-definition monitoring to allow for real-time observation of chamber operations, with support for video recording and traceability. Key parameters—such as temperature, humidity, CO₂ concentration, pressure differential, and leak rates—are monitored in real time. If any parameter falls outside the established range, the system triggers an automatic audible and visual alarm and logs the anomaly for subsequent troubleshooting. Some intelligent systems also feature non-contact density detection modules, which can automatically measure cell density and adjust fluid volumes, eliminating the need for repeated sampling and the associated risk of contamination.
Q: Data Integration and Management
A: The system supports integration with Laboratory Information Management Systems (LIMS) and Manufacturing Execution Systems (MES), enabling centralized management and traceability of operational parameters, environmental conditions, and cell preparation data. Data can be exported or printed to meet GMP audit requirements and scientific data retention needs. For large-scale production equipment, the system also enables intelligent sample management—allowing for rapid, precise retrieval of samples from cryogenic environments, with automated planning of the most efficient access routes.
(V) Equipment Stability and Durability
As core equipment intended for long-term use, the stability and durability of a cell therapy isolator directly impact its service life and operating costs. Key considerations include the materials used, the quality of core components, and the structural design.
✅ Materials: The interior walls of the processing chamber must be constructed from corrosion-resistant, easy-to-clean materials that do not shed particles (e.g., 316L stainless steel or high-borosilicate glass) to prevent contamination of cell products. Gloves and seals must be made from materials resistant to aging and biological decontaminants, ensuring long-term sealing integrity and safety. All tubing materials must be verified for biocompatibility and pressure resistance.
✅ Quality of Core Components: Core components—such as compressors, fans, sensors, and controllers—should be sourced from reputable brands to ensure stable operation and minimize the risk of failure. Critical components like HEPA filters and VHP generators should offer a long service life and be easy to replace or maintain, thereby reducing long-term operational costs. Quality inspection reports and warranty commitments should be provided for all core components.
✅ Structural Design: The equipment’s structure should be well-designed to facilitate daily cleaning, disinfection, and maintenance, ensuring there are no "dead zones" that are difficult to sanitize. Critical components (such as filters and gloves) should be easy to replace without requiring specialized personnel. The equipment should be highly stable, characterized by minimal vibration and low noise during operation, so as not to disrupt the cell culture environment or the workspace for operators.
(VI) Cost and Ease of Operation and Maintenance
When selecting equipment, it is essential to balance initial procurement costs with long-term operational and maintenance expenses. Avoid unnecessary expenditure on high-end configurations that do not provide added value. Furthermore, ensure that the equipment is easy to operate and maintain, which helps minimize downtime and guarantees the continuity of cell preparation processes.
✅ Procurement Costs: Select configurations tailored to specific application scenarios and core requirements to avoid over-specification (e.g., research-grade equipment does not necessarily require high-end automated systems). Compare quotes and configurations from various suppliers to identify the best value for money. Additionally, align procurement with government purchasing policies by prioritizing suppliers and products that meet official requirements, thereby reducing overall procurement costs.
✅ Operational and Maintenance Costs: Prioritize energy-efficient equipment by considering factors such as power and gas consumption. Ensure that the replacement costs for core components—such as filters, gloves, and decontamination agents—are reasonable and that these items are readily available to prevent equipment downtime caused by shortages. Furthermore, HEPA filters must undergo annual leak testing, and VHP (vaporized hydrogen peroxide) generators require periodic calibration.
✅ Operational and Maintenance Convenience: The equipment’s user interface must be intuitive and easy to understand, allowing operators to get up to speed quickly. The supplier must provide comprehensive training to ensure operators are proficient in equipment operation, routine maintenance, and troubleshooting. Furthermore, the equipment must be backed by robust after-sales support, including timely on-site repair services. A clear warranty period for the entire unit should be defined (ideally no less than 3 years), and the contractual delivery timeline must align with the project schedule (e.g., delivery within one month of contract signing).
III. Selection Process and Practical Steps
Requirement Analysis and Supplier Screening
Based on the aforementioned core prerequisites and performance indicators, a standardized selection process should be established. This ensures an orderly selection workflow, achieves a precise match between the equipment and its intended application, and mitigates procurement risks.
Q: Requirements Analysis and Consolidation
A: Form a selection committee—comprising members from technical, clinical/research, procurement, and operations/maintenance departments—to define the organization’s core requirements. These include the application context (clinical, research, or production), the types and batch sizes of cells being processed, regulatory compliance, budget constraints, and internal operational/maintenance capabilities. Prioritize these requirements by distinguishing between "mandatory criteria" (such as sterility standards and regulatory certifications) and "optional features" (such as advanced automation). Documenting these in a formal requirements list helps prevent selection errors caused by vague specifications. Additionally, gather market intelligence—by attending industry exhibitions, reviewing professional literature, or consulting with peers—to evaluate the performance and reputation of various equipment brands.
Q: Supplier Screening and Evaluation
A: Based on the requirements list, identify suppliers that possess the necessary legal qualifications, a strong industry reputation, and solid technical expertise. Prioritize suppliers that hold relevant manufacturing licenses and quality certifications, and who can demonstrate successful track records in similar applications (e.g., a hospital should seek a supplier with experience in clinical-grade isolators, while a commercial enterprise should look for a supplier with expertise in large-scale production equipment). Evaluate each supplier’s technical support capabilities, after-sales service standards, and the availability of spare parts. Where necessary, conduct on-site visits to gain a firsthand understanding of the supplier’s production scale, manufacturing processes, and quality control standards, thereby avoiding vendors that lack proper qualifications or reliable after-sales support.
Q: Equipment Parameter Comparison and Selection
A: Issue requests for quotations (RFQs) and technical specifications to the shortlisted suppliers. Require them to provide detailed equipment parameters, proof of regulatory compliance, case studies, operational and maintenance (O&M) plans, and cost estimates. Evaluate the equipment from various suppliers against your specific requirements and core performance indicators. Focus primarily on whether the equipment meets "mandatory requirements," while also considering "optional features" and total costs. Select 2–3 suppliers that best align with your needs and compile a comparison report outlining the strengths and weaknesses of each piece of equipment.
Q: On-site Inspection and Performance Verification
A: Conduct on-site inspections of the shortlisted suppliers, including visits to their production facilities and R&D centers, to assess their manufacturing processes and quality control systems. Visit other clients—such as similar hospitals or enterprises—that use the same equipment to observe its operational status, stability, and ease of maintenance, and to gather feedback from existing users. Require suppliers to provide a performance verification plan and conduct on-site testing of core performance indicators (e.g., sterility, temperature and humidity control, and containment/sealing). Ensure the equipment meets both your specific requirements and relevant industry standards. Where necessary, perform a media fill test to validate the system’s sterility control capabilities.
IV. Considerations for Model Selection and Common Pitfalls
Prioritize compliance while balancing requirements and future development.
Avoid "Prioritizing Configuration Over Application Context": Do not blindly pursue high-end specifications. Select equipment tailored to your specific operational environment. For instance, research-grade equipment does not necessarily require the high-level clinical compliance or advanced automation found in clinical-grade systems; choosing the latter could lead to underutilized assets and unnecessary costs. Conversely, for clinical-grade applications, compliance and sterility control must be the top priority—never compromise by selecting non-pharmaceutical-grade equipment to cut costs.
Prioritize Verification of Regulatory Compliance: Before procurement, rigorously verify the supplier’s manufacturing credentials, the equipment’s medical device registration certificates, ISO certifications, and other relevant documentation. Ensure that the equipment adheres to industry standards and regulatory requirements to prevent issues such as audit failures or restrictions on clinical use. Pay particular attention to compliance with the YY/T 0567.6—2022 standard. Balancing Short-Term Needs with Long-Term Development: When selecting equipment, consider the organization’s long-term development plan. For instance, a hospital-based cell therapy center might incorporate expansion interfaces for equipment, facilitating the future addition of automated functions or an increase in processing capacity. Similarly, commercial enterprises should prioritize highly scalable equipment capable of adapting to the capacity requirements of large-scale production, thereby avoiding the need for redundant future procurement.
Prioritizing After-Sales Service and Training: The long-term, stable operation of equipment relies on robust after-sales support. Select suppliers that offer prompt response times, strong repair capabilities, and reliable access to spare parts, while ensuring that warranty periods and maintenance procedures are clearly defined. Furthermore, require suppliers to provide comprehensive training to ensure that operators and maintenance personnel possess the necessary skills; this helps minimize operational errors and the incidence of equipment failure. Additionally, ensure that consumable components—such as gloves and filters—are readily available.
Considering Installation Environment Requirements: Isolators have specific environmental requirements. The installation site must be planned in advance to ensure that factors such as floor space, temperature, humidity, cleanliness, power supply, and gas supply meet the equipment’s specifications. Failure to meet these environmental standards can lead to operational issues or degraded performance. For example, the room housing an isolator may require a dedicated drainage system, and the flooring should be treated to be slip-resistant and corrosion-resistant.
Common Pitfalls in Equipment Selection
Cell Therapy Isolators
01: Personnel Training
The misconception that "installing an isolator guarantees total safety" often leads to the neglect of personnel training and the implementation of Standard Operating Procedures (SOPs). This can result in operational errors that pose a contamination risk. Maintaining sterility within an isolator requires a combination of high-performance equipment and strictly regulated operations; personnel must adhere to established protocols and undergo regular training and assessments.
02: Operational Costs
Focusing solely on the initial purchase price while ignoring long-term operational and maintenance costs is a common error. Some lower-priced units feature inferior core components, high energy consumption, and difficult maintenance, leading to a higher total cost of ownership over time. It is essential to evaluate both the purchase price and ongoing operational costs to select the equipment that offers the best overall value.
03: Precise Matching
Confusing the requirements for different application scenarios—such as using research-grade equipment for clinical applications, or clinical-grade equipment for large-scale production—can result in equipment that fails to meet regulatory compliance or capacity requirements, leading to a waste of resources. It is crucial to clearly distinguish between the specific needs of each scenario and ensure that the selected equipment type is precisely matched to those requirements.
04: Compatibility and Scalability
Overlooking equipment compatibility and scalability can render a system incapable of adapting to future optimizations in cell preparation processes or increased production capacity. This may necessitate additional capital expenditure for equipment upgrades or replacements later on. Therefore, it is essential to account for future expansion during the selection phase to ensure the equipment can accommodate long-term development needs.
Selecting an isolator for cell therapy is a systematic undertaking. It should be guided by the core principles of "scenario suitability, regulatory compliance, performance standards, and cost control." By integrating industry standards, specific operational requirements, and market conditions, one can methodically define key selection criteria, adhere to a rigorous selection process, and avoid common pitfalls. As the cell therapy industry rapidly evolves, isolators are transitioning from "premium options" to "standard equipment," with intelligence, automation, and scalability emerging as key development trends. When selecting an isolator, it is crucial to balance immediate requirements with long-term goals. Choosing the right equipment provides a robust guarantee for the safety and efficacy of cell-based products, ultimately facilitating the transition of cell therapy technologies from the laboratory to clinical and industrial-scale applications.
